Giant Cell Arteritis as a Form of Pembrolizumab-Associated Vascular Toxicity
Key Points
To emphasize the significance of diagnosing giant cell arteritis (GCA) in patients on pembrolizumab who present with headaches.
Case presentation of a patient receiving pembrolizumab
Evaluation of symptoms including new headache
Consideration of differential diagnoses
Monitoring of treatment side effects
Identification of GCA in the patient post-treatment with pembrolizumab
Acknowledgment of headache as a potential symptom of vascular toxicity
Highlight of the necessity for clinicians to consider GCA in similar cases
Abstract
This case highlights the importance of considering GCA as a possible diagnosis in patients receiving immune checkpoint inhibitors therapy who report development of new headache.